Patient specific drug screening and biomarker research in pancreatic ductal adenocarcinoma using newly established tumoroids

Recruiting

• Conditions: C25; Malignant neoplasm of pancreas

• Registration Number: DRKS00023315
• Lead Sponsor: niversitätsklinikum Hamburg-Eppendorf

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-26
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

PDAC, sufficient tumor material during pathological processing available, written consent

Exclusion Criteria

tumor material too small in pathological processing, no written consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the successful establishment of a reliable patient-derived PDAC tumoroid protocol and individual chemosensitivity testing protocols

Secondary Outcome Measures

Name	Time	Method
correlation of liquid biopsy mutation status results, tumoroid drug response and the patients' response to chemotherapeutic treatment<br>